Clinical trial

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

NCT03377101

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Copanlisib Normalized identity: copanlisibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fulvestrant Normalized identity: fulvestrantView linked drug · Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Laboratory Biomarker Analysis Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Palbociclib Normalized identity: palbociclibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2018-08-07

PhasePHASE2

Conditions

Estrogen Receptor Positiveunresolved

HER2/Neu Negativeunresolved

Progesterone Receptor Positiveunresolved

Stage IV Breast Cancer AJCC v6 and v7unresolved

Interventions

CopanlisibDRUG · verified · RxNorm: copanlisib

FulvestrantDRUG · verified · RxNorm: fulvestrant

Laboratory Biomarker AnalysisOTHER

PalbociclibDRUG · verified · RxNorm: palbociclib

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03377101 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.